Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
City of Hope National Medical Center, Duarte, California, United States
Stanford Hospital and Clinics, Stanford, California, United States
Sarah Cannon Research Institute, Denver, Colorado, United States
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Rady Children's Hospital-San Diego, San Diego, California, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Cook Children's Medical Center, Fort Worth, Texas, United States
Melanie Ayala Ceja, Los Angeles, California, United States
Karmanos Cancer Center, Detroit, Michigan, United States
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.